Education
About Us
Working with TipRanks
Follow Us
MindWalk Holdings (HYFT)
NASDAQ:HYFT
HYFT Stock Chart & Stats
$1.73
--
Market closed
$1.73
--
Day’s Range― - ―
52-Week Range$0.27 - $3.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.17M
Market Cap
$75.70M
Enterprise Value$75.77M
Total Cash (Recent Filing)$10.66M
Total Debt (Recent Filing)$13.40M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Dec 11, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding46,157,310
10 Day Avg. Volume546,716
30 Day Avg. Volume1,173,323
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.85
Price to Sales (P/S)0.82
P/FCF Ratio-2.80
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue3.09
Enterprise Value/Gross Profit5.59
Enterprise Value/Ebitda-2.63
Forecast
1Y Price Target
$4.00Price Target Upside131.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Canadian Facility GrowthThe expansion of the Canadian facility, with an 83% increase in quarterly orders and a 93% increase in orders from new clients, supports future growth despite the Dutch divestiture.
New Client AcquisitionA recent undisclosed large pharma company signed on as a client to use the platform’s software-as-a-service model.
Rebranding And AI FocusRebranding to showcase AI focus is expected to support greater adoption of BioStrand.
Bears Say
Potential RisksRisks associated with the company's future include commercial, execution, legal, competition, and intellectual property challenges.
MindWalk Holdings News
HYFT FAQ
What was MindWalk Holdings’s price range in the past 12 months?
MindWalk Holdings lowest stock price was $0.27 and its highest was $3.25 in the past 12 months.
What is MindWalk Holdings’s market cap?
MindWalk Holdings’s market cap is $75.70M.
When is MindWalk Holdings’s upcoming earnings report date?
MindWalk Holdings’s upcoming earnings report date is Dec 11, 2025 which is in 43 days.
How were MindWalk Holdings’s earnings last quarter?
MindWalk Holdings released its earnings results on Sep 15, 2025. The company reported -$0.065 earnings per share for the quarter, missing the consensus estimate of -$0.044 by -$0.022.
Is MindWalk Holdings overvalued?
According to Wall Street analysts MindWalk Holdings’s price is currently Undervalued.
Does MindWalk Holdings pay dividends?
MindWalk Holdings does not currently pay dividends.
What is MindWalk Holdings’s EPS estimate?
MindWalk Holdings’s EPS estimate is -0.04.
How many shares outstanding does MindWalk Holdings have?
MindWalk Holdings has 46,157,310 shares outstanding.
What happened to MindWalk Holdings’s price movement after its last earnings report?
MindWalk Holdings reported an EPS of -$0.065 in its last earnings report, missing expectations of -$0.044. Following the earnings report the stock price went down -20.362%.
Which hedge fund is a major shareholder of MindWalk Holdings?
Currently, no hedge funds are holding shares in HYFT
MindWalk Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (131.21% Upside)
$4.00 (131.21% Upside)
Blogger Sentiment
Bullish
HYFT Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
155.16%
12-Months-Change
Fundamentals
Return on Equity
-110.94%
Trailing 12-Months
Asset Growth
-31.34%
Trailing 12-Months
Company Description
MindWalk Holdings
ImmunoPrecise Antibodies (IPA) is a biotechnology company specializing in the development and production of high-quality monoclonal antibodies and other related biopharmaceutical products. Based in Canada, IPA operates primarily in the life sciences sector, focusing on therapeutic and diagnostic applications in various fields including oncology, autoimmune diseases, and infectious diseases. The company's core services include custom antibody development, antibody discovery, and characterization, along with offering a suite of proprietary technologies aimed at accelerating drug development processes.
HYFT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for MindWalk, driven by record revenue growth, improved financial health, and strategic advancements, including a successful rebranding and strengthening of their balance sheet. However, the presence of a net loss and ongoing restructuring challenges indicate areas for further improvement.View all HYFT earnings summariesHYFT Stock 12 Month Forecast
Average Price Target
$4.00
▲(131.21% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―